William Vainchenker

List of Publications by Year in Descending Order

154 papers	15,307 citations	65 h-index	123 g-index
164 ext. papers	17,194 ext. citations	5.9 avg, IF	6.04 L-index

#	Paper	IF	Citations
154	Macrophage migration inhibitory factor is overproduced through EGR1 in TET2 resting monocytes.. *Communications Biology*, **2022**, 5, 110	6.7	0
153	JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML. *Journal of Experimental Medicine*, **2021**, 218,	16.6	7
152	Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms. *Blood*, **2021**, 138, 2142-2148	2.2	3
151	CALR mutant protein rescues the response of MPL p.R464G variant associated with CAMT to eltrombopag. *Blood*, **2021**, 138, 480-485	2.2	2
150	Dual role of EZH2 in megakaryocyte differentiation. *Blood*, **2021**, 138, 1603-1614	2.2	0
149	Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms. *Leukemia*, **2021**,	10.7	1
148	Induced Pluripotent Stem Cells Enable Disease Modeling and Drug Screening in Calreticulin del52 and ins5 Myeloproliferative Neoplasms. *HemaSphere*, **2021**, 5, e593	0.3	2
147	Functional Consequences of Mutations in Myeloproliferative Neoplasms. *HemaSphere*, **2021**, 5, e578	0.3	4
146	CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients. *Haematologica*, **2021**, 106, 863-864	6.6	2
145	IFN: Jekyll and Hyde. *Blood*, **2021**, 137, 291-293	2.2	
144	in acute myeloid leukemia (AML): high prevalence of germline predisposition in French West Indies. *Leukemia and Lymphoma*, **2021**, 62, 1770-1773	1.9	2
143	Role of Rho-GTPases in megakaryopoiesis. *Small GTPases*, **2021**, 12, 399-415	2.7	1
142	Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFN in myeloproliferative neoplasms. *Blood*, **2021**, 138, 2231-2243	2.2	8
141	Lyl-1 regulates primitive macrophages and microglia development. *Communications Biology*, **2021**, 4, 1382	6.7	1
140	Regulation of Platelet Production and Life Span: Role of Bcl-xL and Potential Implications for Human Platelet Diseases. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	7
139	A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemia. *Blood Reviews*, **2020**, 42, 100712	11.1	7
138	Germline genetic factors in the pathogenesis of myeloproliferative neoplasms. *Blood Reviews*, **2020**, 42, 100710	11.1	6

137	Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms. *Oncogene*, **2020**, 39, 5323-5337	9.2	7
136	TET2 haploinsufficiency alters reprogramming into induced pluripotent stem cells. *Stem Cell Research*, **2020**, 44, 101755	1.6	3
135	The Pediatric Acute Leukemia Fusion Oncogene ETO2-GLIS2 Increases Self-Renewal and Alters Differentiation in a Human Induced Pluripotent Stem Cells-Derived Model. *HemaSphere*, **2020**, 4, e319	0.3	4
134	A new efficient tool for non-invasive diagnosis of fetomaternal platelet antigen incompatibility. *British Journal of Haematology*, **2020**, 190, 787-798	4.5	2
133	Immunosuppression by Mutated Calreticulin Released from Malignant Cells. *Molecular Cell*, **2020**, 77, 748-760.e9	17.6	45
132	Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN. *Nature Communications*, **2020**, 11, 4886	17.4	12
131	Megakaryocytes tame erythropoiesis with TGF1. *Blood*, **2020**, 136, 1016-1017	2.2	1
130	Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia. *Haematologica*, **2020**, 105, 112-123	6.6	8
129	Megakaryocyte polyploidization: role in platelet production. *Platelets*, **2020**, 31, 707-716	3.6	10
128	Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development. *Leukemia*, **2020**, 34, 510-521	10.7	23
127	The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications. *Expert Review of Hematology*, **2019**, 12, 437-448	2.8	14
126	Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants. *Blood*, **2019**, 133, 2669-2681	2.2	45
125	Remodeling of Bone Marrow Hematopoietic Stem Cell Niches Promotes Myeloid Cell Expansion during Premature or Physiological Aging. *Cell Stem Cell*, **2019**, 25, 407-418.e6	18	114
124	Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells. *Blood*, **2019**, 134, 2383-2387	2.2	13
123	Disrupted filamin A/ interaction induces macrothrombocytopenia by increasing RhoA activity. *Blood*, **2019**, 133, 1778-1788	2.2	19
122	Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice. *Oncogene*, **2019**, 38, 1651-1660	9.2	5
121	New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis. *Haematologica*, **2018**, 103, 575-586	6.6	9
120	Myelodysplastic Syndromes: Mechanisms, Diagnosis, and Treatment **2018**, 563-563		

119	Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy. *Blood*, **2018**, 132, 4-4	2.2	24
118	Megakaryocyte and polyploidization. *Experimental Hematology*, **2018**, 57, 1-13	3.1	42
117	JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. *F1000Research*, **2018**, 7, 82	3.6	83
116	P53 deletion and NrasG12D cooperate for AML. *Blood*, **2017**, 129, 271-273	2.2	
115	Acquired TET2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of pre-leukaemic clone resulting in T2-ALL and AML-M0. *Journal of Cellular and Molecular Medicine*, **2017**, 21, 1237-1242	5.6	8
114	Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. *Blood*, **2017**, 129, 667-679	2.2	275
113	Critical role of the HDAC6-cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect. *Nature Communications*, **2017**, 8, 1786	17.4	28
112	CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner. *Oncotarget*, **2017**, 8, 54082-54095	3.3	22
111	Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis. *Frontiers in Endocrinology*, **2017**, 8, 234	5.7	23
110	Identification of R102P Mutation in Hereditary Thrombocytosis. *Frontiers in Endocrinology*, **2017**, 8, 235	5.7	15
109	Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. *Journal of Clinical Investigation*, **2017**, 127, 1316-1320	15.9	47
108	Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. *Blood*, **2016**, 127, 1317-24	2.2	178
107	Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. *Blood*, **2016**, 127, 1325-35	2.2	204
106	Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. *Nature Communications*, **2016**, 7, 10767	17.4	140
105	TET2-mediated 5-hydroxymethylcytosine induces genetic instability and mutagenesis. *DNA Repair*, **2016**, 43, 78-88	4.3	16
104	ATG2B and GSKIP: 2 new genes predisposing to myeloid malignancies. *Molecular and Cellular Oncology*, **2016**, 3, e1094564	1.2	7
103	P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis. *Oncotarget*, **2016**, 7, 31980-92	3.3	23
102	Recent advances in understanding myelofibrosis and essential thrombocythemia. *F1000Research*, **2016**, 5,	3.6	29

101	Uncoupling of the Hippo and Rho pathways allows megakaryocytes to escape the tetraploid checkpoint. *Haematologica*, **2016**, 101, 1469-1478	6.6	12
100	An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L. *Blood*, **2016**, 128, 3146-3158	2.2	13
99	Activity of nonmuscle myosin II isoforms determines localization at the cleavage furrow of megakaryocytes. *Blood*, **2016**, 128, 3137-3145	2.2	14
98	Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. *Blood*, **2016**, 127, 333-42	2.2	113
97	EZH2: a molecular switch of the MPN phenotype. *Blood*, **2016**, 127, 3297-8	2.2	2
96	Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. *Nature Genetics*, **2015**, 47, 1131-40	36.3	83
95	Concise Review: Induced Pluripotent Stem Cells as New Model Systems in Oncology. *Stem Cells*, **2015**, 33, 2887-92	5.8	8
94	JAK/STAT Signalling and Haematological Malignancies **2015**, 1-20		
93	Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia. *Blood*, **2015**, 125, 930-40	2.2	66
92	TET2 loss, a rescue of JAK2V617F HSCs. *Blood*, **2015**, 125, 212-3	2.2	1
91	A CALR mutation preceding BCR-ABL1 in an atypical myeloproliferative neoplasm. *New England Journal of Medicine*, **2015**, 372, 688-90	59.2	35
90	Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. *Blood*, **2014**, 123, 1372-83	2.2	59
89	Acquired initiating mutations in early hematopoietic cells of CLL patients. *Cancer Discovery*, **2014**, 4, 1088-101	24.4	172
88	TET2 deficiency inhibits mesoderm and hematopoietic differentiation in human embryonic stem cells. *Stem Cells*, **2014**, 32, 2084-97	5.8	32
87	The formin DIAPH1 (mDia1) regulates megakaryocyte proplatelet formation by remodeling the actin and microtubule cytoskeletons. *Blood*, **2014**, 124, 3967-77	2.2	49
86	Defective endomitosis during megakaryopoiesis leads to thrombocytopenia in Fanca-/- mice. *Blood*, **2014**, 124, 3613-23	2.2	17
85	A new form of macrothrombocytopenia induced by a germ-line mutation in the PRKACG gene. *Blood*, **2014**, 124, 2554-63	2.2	59
84	JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation. *Blood*, **2014**, 124, 2104-15	2.2	34

83	Emergence of a BCR-ABL translocation in a patient with the JAK2V617F mutation: evidence for secondary acquisition of BCR-ABL in the JAK2V617F clone. *Journal of Clinical Oncology*, **2014**, 32, e76-9	2.2	16
82	p19 INK4d controls hematopoietic stem cells in a cell-autonomous manner during genotoxic stress and through the microenvironment during aging. *Stem Cell Reports*, **2014**, 3, 1085-102	8	21
81	Genetic basis of congenital erythrocytosis: mutation update and online databases. *Human Mutation* , **2014**, 35, 15-26	4.7	82
80	Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy. *Clinical Lymphoma, Myeloma and Leukemia*, **2014**, 14 Suppl, S23-35	2	21
79	Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation. *Journal of Clinical Investigation*, **2014**, 124, 580-91	15.9	119
78	Calr Mutants Retroviral Mouse Models Lead to a Myeloproliferative Neoplasm Mimicking an Essential Thrombocythemia Progressing to a Myelofibrosis. *Blood*, **2014**, 124, 157-157	2.2	8
77	Clonal architecture of chronic myelomonocytic leukemias. *Blood*, **2013**, 121, 2186-98	2.2	189
76	Prognostic score including gene mutations in chronic myelomonocytic leukemia. *Journal of Clinical Oncology*, **2013**, 31, 2428-36	2.2	373
75	Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors. *Journal of Cellular and Molecular Medicine*, **2013**, 17, 1397-409	5.6	43
74	Concomitant germ-line RUNX1 and acquired ASXL1 mutations in a T-cell acute lymphoblastic leukemia. *European Journal of Haematology*, **2013**, 91, 277-9	3.8	21
73	JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN*Blood*, **2013**, 122, 1464-77	2.2	95
72	Heterozygous and homozygous JAK2(V617F) states modeled by induced pluripotent stem cells from myeloproliferative neoplasm patients. *PLoS ONE*, **2013**, 8, e74257	3.7	23
71	TET2, a tumor suppressor in hematological disorders. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2012**, 1825, 173-7	11.2	13
70	Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. *Blood*, **2012**, 119, 4625-35	2.2	37
69	Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression. *Blood*, **2012**, 120, 2708-18	2.2	75
68	MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations. *Blood*, **2012**, 120, 2719-22	2.2	61
67	RUNX1-induced silencing of non-muscle myosin heavy chain IIB contributes to megakaryocyte polyploidization. *Nature Communications*, **2012**, 3, 717	17.4	107
66	Presence of a defect in karyokinesis during megakaryocyte endomitosis. *Cell Cycle*, **2012**, 11, 4385-9	4.7	18

65	Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia. *Blood*, **2011**, 118, 6310-20	2.2	43
64	Monocytic cells derived from human embryonic stem cells and fetal liver share common differentiation pathways and homeostatic functions. *Blood*, **2011**, 117, 3065-75	2.2	41
63	Thrombocytopenia resulting from mutations in filamin A can be expressed as an isolated syndrome. *Blood*, **2011**, 118, 5928-37	2.2	128
62	TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. *Cancer Cell*, **2011**, 20, 25-38	24.3	653
61	Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. *Journal of Clinical Oncology*, **2011**, 29, 573-82	2.2	238
60	New mutations and pathogenesis of myeloproliferative neoplasms. *Blood*, **2011**, 118, 1723-35	2.2	316
59	FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis. *Cancer Research*, **2011**, 71, 2901-15	10.1	39
58	Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. *Blood*, **2011**, 118, 2551-5	2.2	139
57	Orientation-specific signalling by thrombopoietin receptor dimers. *EMBO Journal*, **2011**, 30, 4398-413	13	57
56	A senescence-like cell-cycle arrest occurs during megakaryocytic maturation: implications for physiological and pathological megakaryocytic proliferation. *PLoS Biology*, **2010**, 8, e1000476	9.7	73
55	Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. *Blood*, **2010**, 115, 1037-48	2.2	56
54	A major role of TGF-beta1 in the homing capacities of murine hematopoietic stem cell/progenitors. *Blood*, **2010**, 116, 1244-53	2.2	27
53	Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. *Blood*, **2010**, 116, 783-7	2.2	129
52	Aurora B is dispensable for megakaryocyte polyploidization, but contributes to the endomitotic process. *Blood*, **2010**, 116, 2345-55	2.2	34
51	Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. *Blood*, **2010**, 115, 2891-900	2.2	224
50	Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. *Blood*, **2010**, 116, 1132-5	2.2	105
49	TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. *Haematologica*, **2009**, 94, 1676-81	6.6	198
48	An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. *Journal of Experimental Medicine*, **2009**, 206, 1701-7	16.6	66

47	Mutation in TET2 in myeloid cancers. *New England Journal of Medicine*, **2009**, 360, 2289-301	59.2	1376
46	Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. *Blood*, **2009**, 114, 1628-32	2.2	84
45	Molecular and genetic bases of myeloproliferative disorders: questions and perspectives. *Clinical Lymphoma and Myeloma*, **2009**, 9 Suppl 3, S329-39		11
44	Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. *Blood*, **2009**, 114, 1842-51	2.2	21
43	A common bipotent progenitor generates the erythroid and megakaryocyte lineages in embryonic stem cell-derived primitive hematopoiesis. *Blood*, **2009**, 114, 1506-17	2.2	123
42	MAL/SRF complex is involved in platelet formation and megakaryocyte migration by regulating MYL9 (MLC2) and MMP9. *Blood*, **2009**, 114, 4221-32	2.2	63
41	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). *Blood*, **2009**, 114, 3285-91	2.2	231
40	The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. *Journal of Clinical Investigation*, **2009**, 119, 852-64	15.9	75
39	JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. *Seminars in Cell and Developmental Biology*, **2008**, 19, 385-93	7.5	137
38	A nonsynonymous SNP in the ITGB3 gene disrupts the conserved membrane-proximal cytoplasmic salt bridge in the alphaIIbbeta3 integrin and cosegregates dominantly with abnormal proplatelet formation and macrothrombocytopenia. *Blood*, **2008**, 111, 3407-14	2.2	81
37	P19INK4D links endomitotic arrest and megakaryocyte maturation and is regulated by AML-1. *Blood*, **2008**, 111, 4081-91	2.2	44
36	JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. *Blood*, **2008**, 112, 1402-12	2.2	140
35	Activating mutations in human acute megakaryoblastic leukemia. *Blood*, **2008**, 112, 4220-6	2.2	121
34	The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. *Blood*, **2008**, 112, 2429-38	2.2	90
33	Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling. *Blood*, **2008**, 112, 3164-74	2.2	144
32	Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. *Blood*, **2007**, 110, 3735-43	2.2	84
31	Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. *Blood*, **2007**, 109, 71-7	2.2	135
30	Proplatelet formation is regulated by the Rho/ROCK pathway. *Blood*, **2007**, 109, 4229-36	2.2	139

29	Interrelation between polyploidization and megakaryocyte differentiation: a gene profiling approach. *Blood*, **2007**, 109, 3225-34	2.2	85
28	The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. *Blood*, **2007**, 110, 1013-21	2.2	152
27	Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. *Blood*, **2007**, 109, 2202-4	2.2	103
26	New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients. *Seminars in Thrombosis and Hemostasis*, **2006**, 32, 341-51	5.3	30
25	Deficiency in the Wiskott-Aldrich protein induces premature proplatelet formation and platelet production in the bone marrow compartment. *Blood*, **2006**, 108, 134-40	2.2	155
24	Monocyte/macrophage dysfunctions do not impair the promotion of myelofibrosis by high levels of thrombopoietin. *Journal of Immunology*, **2006**, 176, 6425-33	5.3	20
23	Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. *Blood*, **2006**, 108, 346-52	2.2	195
22	Reduced retention of radioprotective hematopoietic cells within the bone marrow microenvironment in CXCR4-/- chimeric mice. *Blood*, **2006**, 107, 2243-51	2.2	95
21	An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. *Blood*, **2006**, 107, 1864-71	2.2	115
20	Mammalian target of rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation. *Blood*, **2006**, 107, 2303-10	2.2	76
19	The SCL relative LYL-1 is required for fetal and adult hematopoietic stem cell function and B-cell differentiation. *Blood*, **2006**, 107, 4678-86	2.2	63
18	JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. *Blood*, **2006**, 108, 1652-60	2.2	362
17	High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. *Blood*, **2006**, 108, 2037-40	2.2	200
16	RGS16 is a negative regulator of SDF-1-CXCR4 signaling in megakaryocytes. *Blood*, **2005**, 106, 2962-8	2.2	80
15	A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. *Nature* , **2005**, 434, 1144-8	50.4	2769
14	JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. *Journal of Biological Chemistry*, **2005**, 280, 41893-9	5.4	128
13	Mechanisms of WASp-mediated hematologic and immunologic disease. *Blood*, **2004**, 104, 3454-62	2.2	122
12	Differential regulation of actin stress fiber assembly and proplatelet formation by alpha2beta1 integrin and GPVI in human megakaryocytes. *Blood*, **2004**, 104, 3117-25	2.2	83

11	FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia. *Journal of Clinical Investigation*, **2004**, 114, 77-84	15.9	133
10	Megakaryocyte polyploidization is associated with a functional gene amplification. *Blood*, **2003**, 101, 541-4	2.2	70
9	Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. *Blood*, **2002**, 100, 3495-503	2.2	192
8	Distinct effects of thrombopoietin depending on a threshold level of activated Mpl in BaF-3 cells. *Journal of Cell Science*, **2002**, 115, 2329-2337	5.3	14
7	Asymmetrical segregation of chromosomes with a normal metaphase/anaphase checkpoint in polyploid megakaryocytes. *Blood*, **2001**, 97, 2238-47	2.2	45
6	Role of p21(Cip1/Waf1) in cell-cycle exit of endomitotic megakaryocytes. *Blood*, **2001**, 98, 3274-82	2.2	59
5	Phenotypic and Functional Evidence for the Expression of CXCR4 Receptor During Megakaryocytopoiesis. *Blood*, **1999**, 93, 1511-1523	2.2	105
4	The Thrombocytopenia of Wiskott Aldrich Syndrome Is Not Related to a Defect in Proplatelet Formation. *Blood*, **1999**, 94, 509-518	2.2	79
3	Effects of Cytokines on Platelet Production From Blood and Marrow CD34+ Cells. *Blood*, **1998**, 91, 830-843	2.2	114
2	Endomitosis of Human Megakaryocytes Are Due to Abortive Mitosis. *Blood*, **1998**, 91, 3711-3723	2.2	147
1	High Thrombopoietin Production by Hematopoietic Cells Induces a Fatal Myeloproliferative Syndrome in Mice. *Blood*, **1997**, 90, 4369-4383	2.2	196